EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Test–retest repeatability of organ uptake on PSMA‐targeted 18 F‐DCFPyL PET/CT in patients with prostate cancer

Rudolf A Werner iD, Susanne Lütje, Bilêl Habacha, Lena Bundschuh, Takahiro Higuchi, Andreas K Buck, Aleksander Kosmala, Constantin Lapa, Markus Essler, Martin A Lodge, Kenneth J Pienta, Mario A Eisenberger und 5 weitere

The Prostate · 2023-09 · 83 (12) · 1186-1192

DOI: 10.1002/pros.24577 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Prostate, online erschienen am 21.05.2023. Verfasst von Rudolf A Werner und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Prostatic Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

We evaluated 18 F‐DCFPyL test–retest repeatability of uptake in normal organs.

Methods

Twenty‐two prostate cancer (PC) patients underwent two 18 F‐DCFPyL PET scans within 7 days within a prospective clinical trial (NCT03793543). In both PET scans, uptake in normal organs (kidneys, spleen, liver, and salivary and lacrimal glands) was quantified. Repeatability was determined by using within‐subject coefficient of variation (wCOV), with lower values indicating improved repeatability.

Results

For SUV mean , repeatability was high for kidneys, spleen, liver, and parotid glands (wCOV, range: 9.0%–14.3%) and lower for lacrimal (23.9%) and submandibular glands (12.4%). For SUV max , however, the lacrimal (14.4%) and submandibular glands (6.9%) achieved higher repeatability, while for large organs (kidneys, liver, spleen, and parotid glands), repeatability was low (range: 14.1%–45.2%).

Conclusion

We found acceptable repeatability of uptake on 18 F‐DCFPyL PET for normal organs, in particular for SUV mean in the liver or parotid glands. This may have implications for both PSMA‐targeted imaging and treatment, as patient selection for radioligand therapy and standardized frameworks for scan interpretation (PROMISE, E‐PSMA) rely on uptake in those reference organs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron Emission Tomography Computed TomographyProstatic NeoplasmsHumansMaleLysineProspective StudiesUreaAntigens, SurfaceGlutamate Carboxypeptidase II

Stichwörter der Autor:innen

18F-DCFPyLE-PSMAPROMISEPSMA-PET/CTorgan uptakeprostate cancerradioligand therapytheranostics

Substanzen

LysineUreaFOLH1 protein, humanAntigens, SurfaceGlutamate Carboxypeptidase II2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid

Autor:innen und Institutionen

  • Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany.
  • The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Department of Nuclear Medicine, University Hospital Aachen, Aachen, Germany.
  • Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany.
  • Nuclear Medicine, Faculty of Medicine, University of Augsburg, Augsburg, Germany.
  • Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.

ORCID-Profile: Rudolf A Werner, Mark C Markowski, Steven P Rowe

Zitieren

APA

Werner, R. A., Lütje, S., Habacha, B., Bundschuh, L., Higuchi, T., Buck, A. K., Kosmala, A., Lapa, C., Essler, M., Lodge, M. A., Pienta, K. J., Eisenberger, M. A., Markowski, M. C., Gorin, M. A., Pomper, M. G., Rowe, S. P., & Bundschuh, R. A. (2023). Test–retest repeatability of organ uptake on PSMA‐targeted 18 F‐DCFPyL PET/CT in patients with prostate cancer. The Prostate, 83(12), 1186-1192. https://doi.org/10.1002/pros.24577

Vancouver

Werner RA, Lütje S, Habacha B, Bundschuh L, Higuchi T, Buck AK, et al. Test–retest repeatability of organ uptake on PSMA‐targeted 18 F‐DCFPyL PET/CT in patients with prostate cancer. The Prostate. 2023;83(12):1186-1192. doi:10.1002/pros.24577

BibTeX
@article{Werner2023,
  author = {Werner, Rudolf A and Lütje, Susanne and Habacha, Bilêl and Bundschuh, Lena and Higuchi, Takahiro and Buck, Andreas K and Kosmala, Aleksander and Lapa, Constantin and Essler, Markus and Lodge, Martin A and Pienta, Kenneth J and Eisenberger, Mario A and Markowski, Mark C and Gorin, Michael A and Pomper, Martin G and Rowe, Steven P and Bundschuh, Ralph A},
  title = {Test–retest repeatability of organ uptake on PSMA‐targeted 18 F‐DCFPyL PET/CT in patients with prostate cancer},
  journal = {The Prostate},
  year = {2023},
  volume = {83},
  number = {12},
  pages = {1186--1192},
  doi = {10.1002/pros.24577}
}
Kostenlos starten →